[212pb]pb-mp0712
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Explore 12 assets in Urinary Bladder Small Cell Neuroendocrine Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Molecular Partners AG
Modality
radiopharmaceutical
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07278479CT.gov Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Small Cell Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [212pb]pb-mp0712 (this asset) | Molecular Partners AG | P1/2 | CCC · 48 |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
| Lurbinectedin | National Cancer Institute (NCI) | P2 | CCC |
| [203Pb]Pb-MP0712 | Molecular Partners AG | P1/2 | CCC |
| Avelumab | National Cancer Institute (NCI) | P2 | CCC |
| Pembrolizumab | Jonsson Comprehensive Cancer Center | P1 | CC |
| Carboplatin | Jonsson Comprehensive Cancer Center | P1 | CC |
+3 more in the Urinary Bladder Small Cell Neuroendocrine Carcinoma cohort
Other indications for [212pb]pb-mp0712
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Large Cell Neuroendocrine Carcinoma | — | P1/2 | CCC · 48 |
| Pulmonary Large Cell Neuroendocrine Carcinoma | — | P1/2 | CCC · 48 |
| Small Cell Lung Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [212pb]pb-mp0712 in Urinary Bladder Small Cell Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/212pbpb-mp0712-urinary-bladder-small-cell-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →